Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.26 · Revenue $43.33M · 2 analysts
Est. EPS $-0.36 · Revenue $54.40M · 2 analysts
Est. EPS $0.45 · Revenue $107.25M · 1 analysts
Est. EPS $0.20 · Revenue $112.99M · 1 analysts
EPS €-0.53 · Revenue €2.79M
EPS €-0.25 · Revenue €4.86M
EPS €-0.61 · Revenue €12.62M
EPS €-0.31 · Revenue €12.35M
EPS €-0.09 · Revenue €51.90M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $2.8M | -77.9% | -142.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-49.2M | +0.6% | -29.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | 0.0% | -176.2% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1916.9% | -369.1% | +358.1% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -1764.5% | -350.2% | +403.5% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-34.9M | -379.1% | +31.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1252.6% | -2069.5% | +261.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -104.0% | -129.6% | -119.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.27x | -51.0% | -42.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $62.7M | -43.6% | -32.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.53 vs -0.55 | +2.8% | -0.30 vs -0.14 | -121.0% |
| Revenue Surprise | $2.8M vs $14.7M | -81.1% | $-2.1M vs $2.3M | -191.2% |
Operator: Ladies and gentlemen, thank you for joining us, and welcome to the Innate Pharma Full Year 2025 Earnings Call. [Operator Instructions] I will now hand the conference over to Stephanie Cornen, Vice President of Investor Relations, Communications and Commercial Strategy at Innate Pharma. Please, Stephanie, go ahead. Stephanie Cornen: Thank you. Good morning and good afternoon, everyone, and thank you for joining us for Innate Pharma's Full Year 2025 Business Update and Financial Results Conference Call. The press release and today's presentation are available on the Investor Relations section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. I will briefly cover today's agenda. Our CEO, Jonathan Dickinson, will begin with a strategic overview and outlook. We will then share updates on our 3 priority program, lacutamab, IPH4502 and monalizumab as well as IPH5201 in partnership with AstraZeneca. Speakers will be our CMO, Sonia Quaratino; our COO, Yannis Morel; and I. Frederic Lombard, CFO, will comment our financial results. Jonathan will return with upcoming catalysts and closing remarks before we open the call for Q&A. With that, I'll now hand it over to Jonathan. Jonathan Dickinson: Thank you, Stephanie. Good morning to those joining from the U.S., and good afternoon to our European audience. Turning to Slide 5. Innate Pharma is a focused oncology company with a clear ambition to deliver high-value, differentiated therapies for patients with significant unmet medical need. Our strength lies in our deep expertise in antibody engineering and our ability to translate this into innovative therapeutic approaches, particularly in immuno-oncology and antibody drug conjugates. Over the years, we have built a pipeline of highly differentiated assets built on targets we believe have high potential to deliver meaningful clinical benefit. Today, we're focused on advancing these assets through late-stage development, combining smart, agile execution with a clear line of sight to key clinical and regulatory milestones. Turning to Slide 6. Over the past year, we have taken important steps to deliver on our strategic priorities with an execution-driven organization. As we announced previously, we made the decision to prioritize investment on what we believe are our 3 highest value clinical assets, IPH4502, lacutamab and monalizumab. This strategic focus allows us to concentrate our resources where we see the greatest potential to generate clinical impact and long-term value. In parallel, we continue to leverage our internal expertise and platform capabilities to advance the next generation of ADCs. At the same time, we have streamlined the organization to ensure we are fit for purpose with a more agile structure that supports efficient …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Jonathan E. Dickinson | Chief Executive Officer & Director | EUR 1,095,077 | Male | 1968 | Active |
Sonia Quaratino | Executive Vice President & Chief Medical Officer | EUR 219,264 | — | 1962 | Active |
Yannis Morel | Executive Vice President & Chief Operating Officer | EUR 190,776 | Male | 1973 | Active |
Frederic Lombard | Senior Vice President & Chief Financial Officer | — | Male | 1975 | Active |
Stephanie Cornen | Vice President of Investor Relations, Communication & Commercial Strategy | — | Female | 1987 | Active |
Marc Bonneville | Founder | — | — | 1960 | Active |
Odile Belzunce | VP, Chief of Compliance & Operations Officer and Interim Head of HR | — | Female | 1980 | Active |
Alessandro Moretta | Founder | — | Male | — | Active |
Jean Jacques Fournié | Founder | — | Male | — | Active |
François Romagné | Founder | — | — | 1964 | Active |
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio.
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (NASDAQ:IPHA) on Monday forged a strategic alliance to launch a critical Phase 3 clinical trial targeting a rare form of skin cancer.
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome.
